<DOC>
	<DOCNO>NCT00077415</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 3-AP gemcitabine , work different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This phase II trial study well give 3-AP together gemcitabine second-line therapy work treat patient recurrent stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>3-AP Gemcitabine Second-Line Therapy Treating Patients With Stage III Stage IV Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient stage III IV recurrent non-small cell lung cancer treat 3-AP ( Triapine® ) gemcitabine second-line therapy . Secondary - Determine response duration , median time progression , overall survival patient treat regimen . - Determine toxicity regimen patient . - Determine effect 3-AP ( Triapine® ) gemcitabine pharmacokinetics cellular uptake peripheral mononuclear cell patient treat regimen . OUTLINE : This open-label , multicenter study . Patients stratify accord participate center . Patients receive 3-AP ( Triapine® ) IV 4 hour gemcitabine IV 30 minute day 1 , 8 , 15* . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . NOTE : *For course 1 , gemcitabine administer alone day 1 combination 3-AP ( Triapine® ) day 8 15 . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 15-31 patient accrue study within 7.5-21 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirmed* nonsmall cell lung cancer ( NSCLC ) Stage III IV disease One follow cellular type : Adenocarcinoma Nondiffuse bronchoalveolar cell carcinoma Large cell carcinoma Squamous cell carcinoma NOTE : *A repeat biopsy accessible tumor site require &gt; 5 year elapse since initial diagnosis Progressive disease 1 prior gemcitabinecontaining chemotherapy regimen stage III IV NSCLC must achieve , least , partial response , complete response , stable disease therapy Not primary nonresponder experience progressive disease gemcitabinecontaining chemotherapy Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No glucose6phosphate dehydrogenase ( G6PD ) deficiency Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 50 mL/min Cardiovascular No prior uncontrolled cardiac disease No myocardial infarction within past 12 month No symptomatic congestive heart failure No coronary artery disease No cardiac arrhythmia Pulmonary No uncontrolled symptomatic pulmonary disease No pulmonary disease require oxygen therapy Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except completely treat carcinoma situ cervix nonmelanoma skin cancer No prior allergic reaction attribute compound similar chemical biological composition study agents No concurrent uncontrolled illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>